TrialNature medicine2025

Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial.

Michelle L O'Donoghue et al.PubMed ↗Publisher ↗

No numbers read from the abstract.